Marked improvement of oral intake with nivolumab monotherapy in a
patient with microsatellite instability-high gastric cancer with
insufficient oral intake
- Takatsugu Ogata,
- Yukiya Narita,
- Kazunari Misawa,
- Waki Hosoda,
- Kei Muro
Abstract
This is the first report of marked improvement of oral intake by
third-line nivolumab monotherapy in a gastric cancer patient with
insufficient oral intake and European Cooperative Oncology Group
performance status 2. We should consider immune checkpoint inhibitors
for microsatellite instability-high gastric cancer, regardless of the
patient's general condition.20 May 2020Submitted to Clinical Case Reports 21 May 2020Submission Checks Completed
21 May 2020Assigned to Editor
05 Jun 2020Reviewer(s) Assigned
06 Jul 2020Review(s) Completed, Editorial Evaluation Pending
14 Jul 2020Editorial Decision: Revise Minor
31 Jul 20201st Revision Received
01 Aug 2020Submission Checks Completed
01 Aug 2020Assigned to Editor
01 Aug 2020Review(s) Completed, Editorial Evaluation Pending
03 Aug 2020Reviewer(s) Assigned
24 Aug 2020Editorial Decision: Accept
Jan 2021Published in Clinical Case Reports volume 9 issue 1 on pages 50-56. 10.1002/ccr3.3399 
